The Health Technology Assessment (HTA) Council releases its preliminary recommendation on the government financing of apixaban, dabigatran, and rivaroxaban for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroups of NVAF patients through its inclusion in the Philippine National Formulary.
Appeals will be accepted from 17 March 2023 to 31 March 2023

Kindly see full advisory:
To keep updated on HTA news, visit our website:
Like and follow our FB page:

Like and follow our FB page: